Cargando…

Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection

OBJECTIVE: The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS: This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Couto, Ingrid, Victoria, Marilu, Veloso, Valdiléa G., Rodrigues, Lorena, Grinsztejn, Beatriz, Lacerda, Marcus, Victoria, Flamir, Perazzo, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362235/
https://www.ncbi.nlm.nih.gov/pubmed/28329027
http://dx.doi.org/10.1371/journal.pone.0174453
_version_ 1782516927385567232
author Couto, Ingrid
Victoria, Marilu
Veloso, Valdiléa G.
Rodrigues, Lorena
Grinsztejn, Beatriz
Lacerda, Marcus
Victoria, Flamir
Perazzo, Hugo
author_facet Couto, Ingrid
Victoria, Marilu
Veloso, Valdiléa G.
Rodrigues, Lorena
Grinsztejn, Beatriz
Lacerda, Marcus
Victoria, Flamir
Perazzo, Hugo
author_sort Couto, Ingrid
collection PubMed
description OBJECTIVE: The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS: This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patients with hepatitis C coinfection, liver transplantation or presence of conditions that limit liver (LSM) or spleen stiffness measurement (SSM) were excluded. Blood tests, abdominal ultrasound, SSM and LSM by transient elastography (FibroScan(®)) were performed at the same day. Alcohol consumption was quantified using the AUDIT score and c-ACLD was defined by LSM ≥ 15 kPa performed by an experimented operator blinded for clinical and laboratory data. RESULTS: 101 patients were eligible and few patients were excluded due to negative anti-HDV (n = 7), hepatitis C coinfection (n = 2), liver transplantation (n = 10) and limitation for LSM or SSM (n = 5). Therefore, 77 patients [61% male, age = 43 (IQR,36–52) years] were included. The prevalence of c-ACLD was 57% (n = 44/77). Patients with c-ACLD had a higher rate of detectable HBV viral load (p = 0.039), higher levels of transaminases, GGT, alkaline phosphatases, total bilirubin and INR (p<0.001 for all), as well as lower platelet count and albumin levels (p>0.001 for both) compared to those without c-ACLD. Patients with c-ACLD had higher SSM [65.2 (IQR,33.8–75.0) vs 21.8 (16.5–32.0) kPa; p<0.001] and higher splenic volume [475 (IQR,311–746) vs 154 (112–283) cm(3); p<0.001] compared to those without. Detectable HBV viral load (>10 UI/ml), alkaline phosphatase (per IU/L) and GGT levels (per IU/L) were independently associated with c-ACLD in all multivariate models. Splenic volume [per cm(3),OR = 1.01 (95%CI,1.01–1.02);p = 0.002], SSM [per kPa, OR = 1.04 (1.01–1.07);p = 0.012] and splenomegaly [yes vs no,OR = 28.45 (4.42–182.95);p<0.001] were independently associated with c-ACLD. CONCLUSIONS: The prevalence of c-ACLD was high in patients with chronic HDV infection in western Amazon basin. HBV viral load, liver enzymes and splenic features can be used to predict severe liver disease in HDV-infected patients.
format Online
Article
Text
id pubmed-5362235
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53622352017-04-06 Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection Couto, Ingrid Victoria, Marilu Veloso, Valdiléa G. Rodrigues, Lorena Grinsztejn, Beatriz Lacerda, Marcus Victoria, Flamir Perazzo, Hugo PLoS One Research Article OBJECTIVE: The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS: This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patients with hepatitis C coinfection, liver transplantation or presence of conditions that limit liver (LSM) or spleen stiffness measurement (SSM) were excluded. Blood tests, abdominal ultrasound, SSM and LSM by transient elastography (FibroScan(®)) were performed at the same day. Alcohol consumption was quantified using the AUDIT score and c-ACLD was defined by LSM ≥ 15 kPa performed by an experimented operator blinded for clinical and laboratory data. RESULTS: 101 patients were eligible and few patients were excluded due to negative anti-HDV (n = 7), hepatitis C coinfection (n = 2), liver transplantation (n = 10) and limitation for LSM or SSM (n = 5). Therefore, 77 patients [61% male, age = 43 (IQR,36–52) years] were included. The prevalence of c-ACLD was 57% (n = 44/77). Patients with c-ACLD had a higher rate of detectable HBV viral load (p = 0.039), higher levels of transaminases, GGT, alkaline phosphatases, total bilirubin and INR (p<0.001 for all), as well as lower platelet count and albumin levels (p>0.001 for both) compared to those without c-ACLD. Patients with c-ACLD had higher SSM [65.2 (IQR,33.8–75.0) vs 21.8 (16.5–32.0) kPa; p<0.001] and higher splenic volume [475 (IQR,311–746) vs 154 (112–283) cm(3); p<0.001] compared to those without. Detectable HBV viral load (>10 UI/ml), alkaline phosphatase (per IU/L) and GGT levels (per IU/L) were independently associated with c-ACLD in all multivariate models. Splenic volume [per cm(3),OR = 1.01 (95%CI,1.01–1.02);p = 0.002], SSM [per kPa, OR = 1.04 (1.01–1.07);p = 0.012] and splenomegaly [yes vs no,OR = 28.45 (4.42–182.95);p<0.001] were independently associated with c-ACLD. CONCLUSIONS: The prevalence of c-ACLD was high in patients with chronic HDV infection in western Amazon basin. HBV viral load, liver enzymes and splenic features can be used to predict severe liver disease in HDV-infected patients. Public Library of Science 2017-03-22 /pmc/articles/PMC5362235/ /pubmed/28329027 http://dx.doi.org/10.1371/journal.pone.0174453 Text en © 2017 Couto et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Couto, Ingrid
Victoria, Marilu
Veloso, Valdiléa G.
Rodrigues, Lorena
Grinsztejn, Beatriz
Lacerda, Marcus
Victoria, Flamir
Perazzo, Hugo
Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
title Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
title_full Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
title_fullStr Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
title_full_unstemmed Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
title_short Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
title_sort prevalence and predictors for compensated advanced chronic liver disease (c-acld) in patients with chronic hepatitis delta virus (hdv) infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362235/
https://www.ncbi.nlm.nih.gov/pubmed/28329027
http://dx.doi.org/10.1371/journal.pone.0174453
work_keys_str_mv AT coutoingrid prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT victoriamarilu prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT velosovaldileag prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT rodrigueslorena prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT grinsztejnbeatriz prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT lacerdamarcus prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT victoriaflamir prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection
AT perazzohugo prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection